Can’t wait to welcome you to Indiana University! Congratulations Dr Sugi!

ACE Inhibition to Distinguish Low-Renin Hypertension From Primary Aldosteronism #nephsky www.ahajournals.org/doi/10.1161/...

#Takotsubo Syndrome: Expanding Insights, Unanswered Questions By ACC Magazine #CardioSky #MedSky @accintouch.bsky.social www.acc.org/Latest-in-Ca...

Congratulations to my friend and colleague @brandimwynne.bsky.social on this prestigious #award from ASPET! Well deserved!

Interesting interactive case presentation on an under-recognized cause of hypertension. @anandvaidya17.bsky.social @nejm.org www.nejm.org/doi/10.1056/...

Congratulations @djfehrenbach.bsky.social ! This is a significant achievement and well deserved!

Nice email to open up! #SafetyFirst

🚨 🔬 Your #muscle remembers! 🧠💪 New 📑 by Pilotto et al. reveals that high-intensity interval training imprints an epigenetic memory in human skeletal muscles 🚴‍♂️📈 Even after 3 months of rest! #HIIT #Epigenetics #MuscleMemory #Kickback for the #holiday😉?!? journals.physiology.org/doi/abs/10.1...

#HerAcademicVoice I want to highlight this website and initiative by my friend and colleague Dr Sotto. Check out these profiles of women of color and invite them to speak, collaborate, and learn from them. Spread the word. www.sylksotto.com/heracademicv...

We strongly suggest that academic publishers and other platforms that host research rapidly implement a Share to Bluesky button for their articles. Here's how: docs.bsky.app/docs/advance... #AcademicSky #HigherEd #Altmetrics

#LBCT #SUMMIT trial #AHA24 💥 Treatment with tirzepatide led to ⤵️risk of a composite of death from cardiovascular 🫀 causes or worsening heart failure 🆚 placebo and improved health status in patients with HFpEF+obesity 📎 @NEJM www.nejm.org/doi/full/10....

Despite Primary Aldosteronism being the most common etiology of secondary HTN in middle-aged adults, <2% of the eligible population is ever screened! Really need to start doing more PRA & Aldo levels on our patients with poorly-controlled HTN, risk factors (see below)

The 2024 ESC guideline says all-comers with HTN. It’s been shown to be cost-effective across all-comers. I think Greg Hundemer’s work on the target organ effects of subclinical primary aldo is compelling 👇. I’ve been checking anyone with uncontrolled HTN www.ahajournals.org/doi/10.1161/...